A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3
Cristina Martín-Higueras(Universidad de La Laguna), Bernd Höppe(University of Bonn), Dorrit E. Jacob(Australian National University), Marcin Zaniew(University of Zielona Góra), Cécile Acquaviva(Hospices Civils de Lyon), Przemysław Sikora(Medical University of Lublin), Bodo B. Beck(University of Cologne), Sander F. Garrelfs(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Justine Bacchetta(Université Claude Bernard Lyon 1)
Cited by 55
Related Papers
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
History, epidemiology and regional diversities of urolithiasis
|Pediatric Nephrology|2008|460
The primary hyperoxalurias
|Kidney International|2009|373
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361